250 related articles for article (PubMed ID: 26698850)
21. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
[TBL] [Abstract][Full Text] [Related]
22. [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].
Manger B; Michels H; Nüsslein HG; Schneider M; Sieper J;
Z Rheumatol; 2007 Feb; 66(1):72-5. PubMed ID: 17221253
[TBL] [Abstract][Full Text] [Related]
23. Evaluating the real-world benefits and risks of anti-tumor necrosis factor therapies.
Low A; Hyrich K
J Rheumatol; 2013 Jan; 40(1):4-6. PubMed ID: 23280161
[No Abstract] [Full Text] [Related]
24. Do TNF-blockers reduce or induce uveitis?
Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
[No Abstract] [Full Text] [Related]
25. Prognostic models of drug-induced neutralizing antibody formation in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis treated with TNF-α blockersockers.
Kraev K; Hristov B; Uchikov P; Kraeva M; Geneva-Popova M; Popova S; Basheva-Kraeva Y; Stoyanova NS; Mitkova-Hristova V
Folia Med (Plovdiv); 2024 Apr; 66(2):188-195. PubMed ID: 38690813
[TBL] [Abstract][Full Text] [Related]
26. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Minozzi S; Bonovas S; Lytras T; Pecoraro V; González-Lorenzo M; Bastiampillai AJ; Gabrielli EM; Lonati AC; Moja L; Cinquini M; Marino V; Matucci A; Milano GM; Tocci G; Scarpa R; Goletti D; Cantini F
Expert Opin Drug Saf; 2016 Dec; 15(sup1):11-34. PubMed ID: 27924643
[TBL] [Abstract][Full Text] [Related]
27. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
Seitz M; Wirthmüller U; Möller B; Villiger PM
Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
[TBL] [Abstract][Full Text] [Related]
28. Discordance of Global Assessments by Patient and Physician Is Higher in Female than in Male Patients Regardless of the Physician's Sex: Data on Patients with Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis from the DANBIO Registry.
Lindström Egholm C; Krogh NS; Pincus T; Dreyer L; Ellingsen T; Glintborg B; Kowalski MR; Lorenzen T; Madsen OR; Nordin H; Rasmussen C; Hetland ML
J Rheumatol; 2015 Oct; 42(10):1781-5. PubMed ID: 26233511
[TBL] [Abstract][Full Text] [Related]
29. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
[TBL] [Abstract][Full Text] [Related]
30. Anti-tumour necrosis factor therapy is associated with certain subtypes of chronic rhinosinusitis.
Leonard CG; Masih C; McDonald S; Taylor G; Maiden N; Leyden PJ
J Laryngol Otol; 2016 Jun; 130(6):560-4. PubMed ID: 27121598
[TBL] [Abstract][Full Text] [Related]
31. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
Pfueller CF; Seipelt E; Zipp F; Paul F
Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
[No Abstract] [Full Text] [Related]
32. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
[TBL] [Abstract][Full Text] [Related]
33. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
Glintborg B; Sørensen IJ; Loft AG; Lindegaard H; Linauskas A; Hendricks O; Hansen IMJ; Jensen DV; Manilo N; Espesen J; Klarlund M; Grydehøj J; Dieperink SS; Kristensen S; Olsen JS; Nordin H; Chrysidis S; Dalsgaard Pedersen D; Sørensen MV; Andersen LS; Grøn KL; Krogh NS; Pedersen L; Hetland ML;
Ann Rheum Dis; 2017 Aug; 76(8):1426-1431. PubMed ID: 28473425
[TBL] [Abstract][Full Text] [Related]
34. Retention on anti-tumour necrosis factor therapy: the Waikato experience.
Ip K; Hartley L; Solanki K; White D
N Z Med J; 2015 May; 128(1415):34-40. PubMed ID: 26117510
[TBL] [Abstract][Full Text] [Related]
35. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
36. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.
Kay LJ; Griffiths ID;
Rheumatology (Oxford); 2006 Nov; 45(11):1376-9. PubMed ID: 17040892
[TBL] [Abstract][Full Text] [Related]
37. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Bonovas S; Minozzi S; Lytras T; González-Lorenzo M; Pecoraro V; Colombo S; Polloni I; Moja L; Cinquini M; Marino V; Goletti D; Matucci A; Tocci G; Milano GM; Scarpa R; Cantini F
Expert Opin Drug Saf; 2016 Dec; 15(sup1):35-54. PubMed ID: 27924644
[TBL] [Abstract][Full Text] [Related]
38. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
[TBL] [Abstract][Full Text] [Related]
39. Anti-TNF-alpha therapy for ankylosing spondylitis--a specific or nonspecific treatment?
Dayer JM; Krane SM
N Engl J Med; 2002 May; 346(18):1399-400. PubMed ID: 11986415
[No Abstract] [Full Text] [Related]
40. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
Conti F; Ceccarelli F; Marocchi E; Magrini L; Spinelli FR; Spadaro A; Scrivo R; Valesini G
Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
